Pharming GroupPHAR +2.23%79 PB Ratio is 3.48 as of Jun. 25, 2026, which is 21% below its 10-year median of 4.39. GuruFocus rates PHAR with a GF Score™ of 79/100 and a GF Value™ of $14.23 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,233 Biotechnology companies, Pharming Group ranks worse than 58.64% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), Pharming Group's share price is $13.27. Pharming Group's Book Value per Share for the quarter that ended in Mar. 2026 was $3.81. Hence, Pharming Group's PB Ratio of today is 3.48.
The historical rank and industry rank for Pharming Group's PB Ratio or its related term are showing as below:
PHAR'
s PB Ratio Range Over the Past 10 Years
Min: 2.16 Med: 4.39 Max: 117.36
Current: 3.56
During the past 13 years, Pharming Group's highest PB Ratio was 117.36. The lowest was 2.16. And the median was 4.39.
PHAR's PB Ratio is ranked worse than 58.64% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs PHAR: 3.56
During the past 12 months, Pharming Group's average Book Value Per Share Growth Rate was 13.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 4.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 6.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 25.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Pharming Group was 103.50% per year. The lowest was -60.80% per year. And the median was 6.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Pharming Group PB Ratio Related Terms
Pharming Group PB Ratio Historical Data
* Premium members only.
The historical data trend for Pharming Group's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pharming Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharming Group PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharming Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where Pharming Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Pharming Group's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Pharming Group (PHAR) has a PB Ratio of 3.48 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Pharming Group and its competitors. This is 21% below median its historical median of 4.39. Over the past decade, Pharming Group's PB Ratio has ranged from 2.16 to 117.36. According to the industry distribution chart, Pharming Group ranks #723 out of 1233 companies in the Biotechnology industry, placing it in the top 58.6%.
Is Pharming Group's PB Ratio too high?
Pharming Group's current PB Ratio of 3.48 is 21% below median its 10-year median of 4.39. Over the past 10 years, this metric has ranged from a low of 2.16 to a high of 117.36. The Biotechnology industry median PB Ratio is 2.80. Pharming Group's value of 3.48 is 24.3% above this industry median. Based on the distribution chart, Pharming Group ranks #723 out of 1233 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pharming Group has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharming Group ranks #723 out of 1233 companies for PB Ratio. This places Pharming Group in the lower half of its industry. The industry median PB Ratio is 2.80. Pharming Group's value of 3.48 is 24.3% above this benchmark. Historically, Pharming Group's own PB Ratio has ranged from 2.16 to 117.36 over the past decade. While the company's 10-year median is 4.39 vs. the industry median of 2.80, Pharming Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharming Group's current PB Ratio of 3.48 is 24.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Pharming Group and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharming Group's current PB Ratio is 3.48, which is 21% below median its own 10-year median of 4.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (PHAR) is currently considered Fairly Valued. The stock's GF Value™ is $14.23, compared to a current price of $13.27 — trading 6.7% below its estimated fair value. The current PB Ratio is 3.48, which is 21% below median its 10-year median of 4.39 and 24.3% above the Biotechnology industry median of 2.80. Pharming Group's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Pharming Group (PHAR), the current PB Ratio is 3.48 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharming Group (PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued.
The current stock price of $13.27 is trading 6.7% below its estimated GF Value™ of $14.23.
GuruFocus considers Pharming Group to be Fairly Valued.
Key valuation signals for PHAR:
PB Ratio: 3.48 (21% below median its 10-year median of 4.39)
GF Value™: $14.23 vs. price of $13.27 (6.7% below fair value)
Industry Position: 24.3% above the Biotechnology median (#723 of 1233)
No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
79GF Score
Get the complete analysis for PHAR
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHAR has been successfully added to your 
